A monoclonal antibody (mAb 8281) gaar ah oo loogu talagalay terminal β-galactose (βGal) ee glycosphingolipids (GSL) iyo glycoproteins ayaa laga soo saaray jiirarka laga tallaalay soosaaray dufan ka soo baxay unugyada cusub ee lymphocytic leukemia (ALL).Immuno-khafiifka lakabka chromatography (ITLC) iyo qiimaynta tartanka oo leh heerar GSL dhexdhexaad ah oo la safeeyey, sonkor bilaash ah, iyo neoglycoproteins synthetic ayaa muujiyay mAb 8281 inuu si adag uga falceliyo LacCer, GalCer iyo Gal-β-O- (CH3) 2S (CH3) 2- CONH-(Gal-β-O-CETE) oo ku xidhan serum albumin (BSA).Sonkorta cirifka ah ayaa waliba door ka ciyaartay isku xidhka.Kahortagga jidhku kama falcelin karbohaydraytyo leh qaab-dhismeedyo αGal ah iyo qaybo aan xidhiidh la lahayn.Midabaynta aan tooska ahayn ee immunoperoxidase iyo qulqulka cytometry ee mAb 8281 waxay muujisay midab togan oo ku saabsan unugyo badan, oo ay ku jiraan muruqa siman, xuubka caloosha iyo mindhicirka, unugyada qanjidhada B unugyada iyo monocytes.Falanqaynta ITLC ee halabuurka GSL ee neoplasms unug cusub oo B ah iyadoo la adeegsanayo mAb 8281 waxay xaqiijisay joogitaanka lactosylceramide iyo galactosylceramide ee neoplasms ee heerar kala duwan oo kala duwanaansho ah.Sababtoo ah gaar ahaaneed ee hadhaaga karbohaydrayt ee βGal, mAb 8281 ayaa laga yaabaa inay faa'iido u leedahay falanqaynta qaabdhismeedka iyo shaqeynta ee GSL.
